Clinical Trials Logo

Aspirin clinical trials

View clinical trials related to Aspirin.

Filter by:

NCT ID: NCT03005704 Recruiting - Aspirin Clinical Trials

Reversal of the Antiplatelet Effects of Ticagrelor in Combination With Aspirin, Using Normal Platelets

REVSTARTS
Start date: January 2017
Phase: N/A
Study type: Interventional

The specific objective of this study is to investigate the potential for normal platelets to reverse the inhibition of platelet aggregation in patients treated with ticagrelor in combination with aspirin.

NCT ID: NCT01268917 Recruiting - Clinical trials for Coronary Artery Disease

The Effects of Preoperative Aspirin on Graft Patency and Cardiac Events in Off-pump Coronary Artery Bypass

Start date: March 2010
Phase: Phase 3
Study type: Interventional

Antiplatelet therapy is critical in the management of coronary artery disease.For patients undergoing off-pump coronary artery bypass graft,controversy remains regarding the safety of preoperative antiplatelet therapy.And there is little study about the effect of continuing aspirin until the surgery day on graft patency.So we would like to perform this study to evaluate the effects of preoperative aspirin on graft patency and cardiac events in off-pump coronary bypass.

NCT ID: NCT00978159 Recruiting - Dyspepsia Clinical Trials

Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia

Start date: September 2009
Phase: Phase 4
Study type: Interventional

Aspirin can prevent ischemic vascular disease but is commonly complicated by dyspepsia in 30% of patients. Patients, who have aspirin related dyspepsia, commonly underwent upper endoscopy to exclude peptic ulcer disease or gastric cancers. For those without significant lesions in the stomach and duodenum (non-ulcer dyspepsia), the best approach in the management is unclear. The objective of this study is to compare the efficacy of esomeprazole and famotidine in the control of dyspeptic symptom. After giving consent, patients will be randomised to receive either esomeprazole 20 mg daily or famotidine 40 mg daily in a double blinded manner. The patient will be followed-up at the 2nd and 4th week. The study will be completed at the 4th week. The primary analysis will be the efficacy in the control of dyspepsia symptom between the two groups.